Cargando…
Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?
Prostate cancer remains the most common malignancy among men and the second leading cause of male cancer-related mortality. Death from this disease is invariably due to resistance to androgen deprivation therapy. Our improved understanding of the biology of prostate cancer has heralded a new era in...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375104/ https://www.ncbi.nlm.nih.gov/pubmed/22738151 http://dx.doi.org/10.1007/s13167-011-0138-2 |